Antibody-Drug Conjugates (ADC) Market (2026-2036)

The growth of this market is mainly driven by strong clinical results and rapid label expansion of leading ADCs, large-scale investment by major pharmaceutical companies through acquisitions and licensing, and the rising global cancer burden. However, dose-limiting toxicities, the complexity and cost of ADC manufacturing, high prices and reimbursement barriers, and late-stage clinical setbacks restrain the growth of this market.

Furthermore, bispecific and dual-payload ADCs, novel payload classes, and the use of ADCs in earlier lines of therapy and in combination with immunotherapy are expected to offer growth opportunities for the stakeholders in this market. However, crowding around validated targets, resistance and treatment sequencing, dependence on geopolitically exposed supply chains and partners, and emerging biosimilar competition remain major challenges impacting the growth of this market. Additionally, the shift toward topoisomerase I inhibitor payloads, the rise of China as an ADC innovation hub, consolidation through large acquisitions, and expansion of specialized ADC manufacturing capacity are prominent trends in this market.

The Antibody-Drug Conjugates (ADC) Market comprises therapeutic agents that link a monoclonal antibody, which binds to a specific antigen on the surface of cancer or other diseased cells, to a potent cytotoxic or other payload via a chemical linker, allowing targeted delivery of the payload while limiting exposure of healthy tissue. The market covers ADCs by target, including HER2, TROP2, Nectin-4, hematologic targets such as CD30, CD79b, CD22, and CD33, folate receptor alpha, and emerging targets such as B7-H3, HER3, and c-Met; by payload, including microtubule inhibitors such as MMAE and maytansinoids, topoisomerase I inhibitors such as deruxtecan and SN-38, DNA-damaging agents, and novel payloads; by linker type; and by format, including monospecific, bispecific, and dual-payload ADCs. Indications include breast, urothelial, lung, gastric, and gynecologic cancers and hematologic malignancies. Market value is measured at manufacturer sales of approved products. The ecosystem spans pharmaceutical and biotechnology companies, antibody and linker-payload technology providers, contract development and manufacturing organizations, oncologists and cancer centers, payers, and regulators.

ADCs have become one of the fastest-growing areas in oncology. Combined sales of Enhertu, developed by Daiichi Sankyo and AstraZeneca, rose to USD 4.98 billion in 2025 from USD 3.75 billion in 2024, with U.S. in-market sales of USD 2.45 billion, as the drug became standard of care in HER2-positive and HER2-low metastatic breast cancer and gained uptake in chemotherapy-naive HER2-low and HER2-ultralow disease following the DESTINY-Breast06 trial. Pfizer reported 2025 Padcev revenue of USD 1.94 billion, up 22%, with partner Astellas also recording sales. Other established ADCs include Roche's Kadcyla and Polivy, Pfizer and Takeda's Adcetris, Gilead's Trodelvy, AbbVie's Elahere, and AstraZeneca and Daiichi Sankyo's Datroway, approved in 2025.

Investment has been extraordinary. Pfizer acquired Seagen, the pioneer of vedotin ADCs, for about USD 43 billion in 2023, AbbVie acquired ImmunoGen for about USD 10.1 billion in 2024, and Merck & Co. agreed in 2023 to co-develop three Daiichi Sankyo ADCs in a deal worth up to USD 22 billion, while Johnson & Johnson acquired Ambrx and Genmab acquired ProfoundBio in 2024. Chinese biotechnology companies, including Kelun-Biotech, Hengrui, RemeGen, Duality Biologics, and SystImmune, have become major sources of ADC innovation, licensing assets to global companies such as Merck & Co., BioNTech, and Bristol Myers Squibb, and China approved its own ADCs, including Kelun-Biotech's sacituzumab tirumotecan.

The market faces important challenges. ADCs can cause serious toxicities, such as interstitial lung disease with Enhertu, which carries a boxed warning, and ocular toxicity, which contributed to the withdrawal of Blenrep from the U.S. market in 2022 before its later return. Manufacturing ADCs requires handling highly potent compounds and complex conjugation processes, prices are high, and health technology assessment bodies such as England's NICE have declined to recommend some ADC uses on cost-effectiveness grounds. At the same time, the International Agency for Research on Cancer estimated about 20 million new cancer cases worldwide in 2022, projected to rise to more than 35 million by 2050, underpinning long-term demand.